CD274 and non-small cell lung carcinoma: Our results mirror other RWD results of anti-PD-(L)1 re-challenge where disease control rate has varied from ~ 20% to a bit over 40% with NSCLC patients (Fujita et al. 2020; Niki et al. 2018; Watanabe et al. 2019).